key: cord-0332673-dmy6j8l6 authors: Manikpurage, H. D.; Eslami, A.; Perrot, N.; Li, Z.; Couture, C.; Mathieu, P.; Bosse, Y.; Arsenault, B. J.; Theriault, S. title: A Polygenic Risk Score for Coronary Artery Disease Improves the Prediction of Early-Onset Myocardial Infarction and Mortality in Men date: 2021-04-27 journal: nan DOI: 10.1101/2021.04.25.21256083 sha: 7b4044f393aee1da8a2e45aa8c499199ba3ac265 doc_id: 332673 cord_uid: dmy6j8l6 Background: Several risk factors for coronary artery disease (CAD) have been described, some of which are genetically determined. The use of a polygenic risk score (PRS) could improve CAD risk assessment, but predictive accuracy according to age and sex is not well established. Methods: A PRSCAD including the weighted effects of >1.14 million SNPs associated with CAD was calculated in UK Biobank (n=408,422), using LDPred. Cox regressions were performed, stratified by age quartiles and sex, for incident MI and mortality, with a median follow-up of 11.0 years. Improvement in risk prediction of MI was assessed by comparing PRSCAD to the pooled cohort equation with categorical net reclassification index using a 2% threshold (NRI0.02) and continuous NRI (NRI>0). Results: From 7,746 incident MI cases and 393,725 controls, hazard ratio (HR) for MI reached 1.53 (95% CI [1.49-1.56], p=2.69e-296) per standard deviation (SD) increase of PRSCAD. PRSCAD was significantly associated with MI in both sexes, with a stronger association in men (interaction p=0.002), particularly in those aged between 40-51 years (HR=2.00, 95% CI [1.86-2.16], p=1.93e-72). This group showed the highest reclassification improvement, mainly driven by the up-classification of cases (NRI0.02=0.199, 95% CI [0.157-0.248] and NRI>0=0.602, 95% CI [0.525-0.683]). From 23,982 deaths, HR for mortality was 1.08 (95% CI [1.06-1.09], p=5.46e-30) per SD increase of PRSCAD, with a stronger association in men (interaction p=1.60e-6). Conclusion: Our PRSCAD predicts MI incidence and all-cause mortality, especially in men aged between 40-51 years. PRS could optimize the identification and management of individuals at risk for CAD. Coronary artery disease (CAD) is considered as a global health issue, responsible for a high morbidity and mortality worldwide, especially when presenting as a myocardial infarction (MI) 1 . CAD is heritable and has many recognized risk factors, several of which are genetically driven (e.g. body mass index, LDL-cholesterol, diabetes, blood pressure) while others are related to lifestyle or environment (e.g. smoking, nutritional behaviors, physical activity) 2 . Current treatments for CAD include invasive procedures and preventive medical therapies. Numerous new molecules have been developed or are currently evaluated in clinical studies (e.g. PCSK9 inhibitors, lipoprotein(a) antisense) 3, 4 in order to reverse or slow down CAD progression through its causal risk factors. However, identifying and selecting patients who will benefit from these therapies remains challenging, especially considering the cost of these new treatments. During the past decades, methods to identify high-risk patients have improved. From observational studies, several scores to quantify the risk of developing atherosclerotic cardiovascular disease (ASCVD) were proposed 5, 6 . However, these scores do not consider genetic components and focus only on age-related risk factors or lifestyle habits observed at a given time point. Recent genome-wide association studies (GWAS), including data from up to >700 000 individuals, have uncovered numerous genetic loci associated with CAD 7,8 . These publicly available datasets enable the development of instruments that aggregate the effect of variants located throughout the genome. A polygenic risk score (PRS) can be estimated early in life and identify individuals with a high genetic risk. Recent algorithms, such as the one implemented in LDPred 9 , use Bayesian statistics to generate a posterior mean effect of genetic variants by accounting for nearby polymorphisms (i.e. in linkage disequilibrium), improving the predictive accuracy of the PRS. To date, many PRS for CAD were proposed to establish the genetic risk profile of an individual 2, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . While independently associated with CAD, the incremental value of these PRS to existing tools was shown to be relatively modest 18, 19 . However, the thresholds to define individuals with a high polygenic risk have not been thoroughly explored in these studies. As All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.25.21256083 doi: medRxiv preprint 4 shown previously, the use of a high PRS threshold could identify patients with risk similar to rare monogenic mutations associated with CAD 15, 16 . The predictive accuracy of PRS for incident CAD has also not been reported according to age and sex strata. Here, we evaluated the accuracy of a CAD PRS (PRSCAD) to predict incident MI and mortality in participants from UK Biobank followed for a median of 11.0 years. This study had three main objectives: (1) derive a PRSCAD and evaluate its association with incident MI and mortality according to age and sex, (2) compare its predictive accuracy with other CAD risk factors and existing clinical tools and (3) propose a threshold to identify individuals at high risk who could benefit the most from early preventive measures. We show that PRSCAD is independently associated with incident MI and mortality. These associations are stronger in men aged between 40 and 51 years. We also suggest a threshold that could be used to identify individuals at high risk. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. UKB is linked to Hospital Episode Statistic (HES) data, as well as national death and cancer registries. These databases use normalized diagnostic codes from the International Classification of Diseases (ICD)-10 th revision and surgical procedure codes of OPSC-4 (Office of Population, Censuses and Surveys: Classification of Interventions and Procedures, version 4). To define prevalent CAD, we selected participants with ICD-10 codes for MI (I21.X, I22.X, I23.X, I24.1, or I25.2), for other acute ischemic heart disease (I24.0, I24.8-9) and for atherosclerotic / chronic ischemic heart disease (I25.0-25.1, I25. 5-25.9 For incident analyses, we used first occurrences dates for MI (data-field 131298 -I21 ICD-10) provided by UKB until the end of June 2020. These data are retrieved from death registry, primary care information (available for ~45% of UKB participants), hospital admission medical reports and self-report. Dates for all-cause mortality (data-field 40000) were provided until August 2020. The estimation of 10-year risk of having a first ASCVD event was obtained by applying the pooled cohort equation (PCE) 5 . This equation combines the following common risk factors: ethnicity, sex, age, smoking status (current or not), HDL-cholesterol (HDL-C) levels, total cholesterol levels, diabetes status, systolic blood pressure and treatment against hypertension. Data collected or measured at the baseline assessment in UKB was used. In participants without direct HDL-C measurement, levels were estimated using the Friedewald equation for individuals with triglycerides levels <4.52 mmol/L (<400mg/dL). Otherwise, individuals with missing data for any risk factor were excluded (n =47,735). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Genetic data issued from UKB Phase 3 release were obtained from two genotyping arrays: Affymetrix UK Biobank Axiom and UKBiLEVE Axiom. Quality control procedures, phasing and imputation were centrally performed using UK10K panel, Haplotype Reference Consortium resource and 1000 Genomes Phase 3 panel as references 27 . Samples with a call rate <95%, an outlier heterozygosity rate, a sex mismatch, a non-white British ancestry, a third-degree relatives excess (>10), or not used for relatedness calculation, were excluded. A polygenic score estimating the CAD genetic risk (PRSCAD) was built by using the LDPred software (v1.0.08) 9 . Our study population was divided into two groups: a training dataset of 5,000 randomly selected participants and a validation group including the rest of the cohort (n=403,422, Supplemental Table 1 ). The LDPred algorithm uses a Bayesian approach to generate a posterior mean effect for each variant described in a GWAS, by using information on linkage disequilibrium (LD) of variants found in a reference panel. We used the summary statistics issued from the CAD GWAS metaanalysis of the CARDIoGRAMplusC4D 7 consortium (including 60,801 cases and 123,504 controls). For the LD reference panel, we used data from the 503 European samples from the 1000 Genomes Project (phase 3, version 5) 28 . Variants with info score R2 < 0.3 (i.e. quality of imputation), minor allele frequency (MAF) < 0.01, multi-allelic, insertion or deletions and with MAF discrepancies > 10% between all datasets were excluded. Only SNPs included in the Phase 3 HapMap Consortium (~1.2 million) were kept for the PRS derivation as recommended 9 . This computational algorithm also considers the fraction of causal variants via a tuning parameter called rho, which is unknown for any given trait. A range of rho values (0.1 -0.03 -0.01 -0.003 -0.001 -0.0003) were explored using the training dataset as recommended 9 . The final PRSCAD aggregates the re-weighted effect of 1,145,511 SNPs. From here, the PRSCAD was z-score normalized for further statistical analysis. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To evaluate the association between PRSCAD and prevalent CAD and MI, logistic regressions adjusted for age, sex and the first ten genetic principal components (PCs) were performed. We also tested the independence between the PRSCAD and other CAD-related risk factors, namely LDL-cholesterol, body mass index, systolic blood pressure, diabetes, smoking status and the derived PCE variable. Cox proportional hazard regression models were performed to evaluate the association of PRSCAD with the incidence of a first MI and all-cause mortality. Dates of recruitment were used as the starting time and all participants with events occurring before recruitment were excluded. As data collection timeline differs for each outcome, we selected dates for the end of follow-up according to the frequency distribution in time ( Figure 1 and Supplemental Figures 1-2) . For incident MI, the end of follow-up date was selected within the last two years of the follow-up; each month event frequency was screened and if there was a decrease exceeding 60% of the mean of the previous three-month event frequency, the last day of the three-month period was chosen as the end date (Supplemental Figure 1 ). For all-cause mortality, we used the last day of February 2020 as the end of follow-up date, to avoid the subsequent sharp increase in mortality likely secondary to the COVID-19 pandemic (Supplemental Figure 2 ). Schoenfeld tests were performed as a prior to Cox regressions in order to verify proportionality assumption and Schoenfeld residuals were visually inspected. We stratified our analysis by quartiles of age and by sex. Models were adjusted for age, sex and the first ten genetic PCs in age-stratified analysis and only for age and the first ten genetic PCs in sex-stratified analyses. Models including the derived PCE variable were also tested. To identify thresholds for a high genetic risk, we compared the individuals above the 80 th , 90 th , 95 th , 97.5 th and 99 th percentile of the PRS distribution to the rest of the validation group. To explore survival and incidence of event probabilities, we performed Kaplan-Meier analysis. Tertiles of PRSCAD were used to define genetic risk categories, as well as individuals below and above the 90 th percentile of PRSCAD. Statistical significance through genetic risk categories were assessed via log-rank tests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The discrimination of the predictive models was assessed using Harrell's C-statistic and 95% confidence intervals (CI) were calculated by bootstrapping. PRSCAD predictive performance was evaluated when added to PCE, using categorized net reclassification improvement (NRI), with a risk probabilities threshold of 2% (NRI 0.02 ) obtained with Kaplan-Meier estimates for a period of 10 years. The risk threshold was selected based on the proportion of incident MI in the cohort. Continuous NRI (NRI >0 ) were also calculated to assess the strength of the instrument as were obtained from bootstrapping. All statistical analyses were conducted using R (version 3.5.1) and GraphPad Prism 9. P-values <0.05 were considered as significant. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The complete dataset includes 408,422 participants from European ancestry, with a mean age of 56.9 ± 8.0 years at recruitment and 54.1% of women. From Hospital Episode Statistics data, we have identified 32,694 cases of CAD (8.00%), 14,924 cases of MI (3.65%) and 20,769 cases of MI or revascularization (5.08%) (Supplemental Table 1 ). A PRSCAD including 1,145,511 SNPs was calculated in the training dataset including 5,000 participants. The optimal rho value was 0.01 (Supplemental Table 2 ) with a corresponding odds ratio for CAD (ORCAD) per SD increase of PRSCAD reaching 1.48 (95% CI [1.29 to 1.70], p = 3.45e-08). The PRSCAD was calculated in the validation group, where it was normally distributed (Anderson-Darling Normality Test, p = 0.1468, Supplemental Figure 3 ). In the validation group, including 32,475 CAD cases and 370,947 controls, the ORCAD was 1.56 (95% CI, [1.54 to 1.58, p < 10e-300) per SD increase of PRSCAD ( Figure 2 ). The area under the receiver operating characteristic curve (AUC) was 0.766 for the model including PRSCAD, age, sex and the first ten genetic principal components (Supplemental Table 3 ). ORCAD per SD increase of PRSCAD was higher in men (1.62 -95% CI [1.59 to 1.64], p <10e-300) compared to women (1.45 -95% CI [1.42 to 1.48], p = 3.65e-255; p = 1.21e-18 for interaction) ( Figure 2 ). Likewise, OR for MI (ORMI) and OR for MI-Revascularization (ORMI-REVASC) per SD increase of PRSCAD were higher in men than women (p = 2.39e-06 and p = 0.003 for interaction) ( Figure 2 ). The association between PRSCAD and the cardiovascular outcomes was similar in models adjusted for body mass index, LDL-cholesterol, HDL-cholesterol, total cholesterol, systolic blood pressure, diabetes and smoking status (Supplemental Table 3 ). Similar results were obtained when adjusting for the PCE-derived 10-year risk of first ASCVD variable (Supplemental Table 3 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To determine the predictive accuracy of PRSCAD, we evaluated its association with the incidence of a first MI. A total of 7,746 first MI occurred during the follow-up (median of 11.0 years) ( Table 1 ). There was a significant decrease in PRSCAD in the third and fourth age quartiles (Supplemental Figure 4) . The risk of having a first MI was positively associated with PRSCAD. When including all age groups and both sexes, adjusted hazard ratios (HR) for MI (HRMI) per SD increase of PRSCAD was 1.53 (95% CI [1.49 to 1.56], p = 2.69e-296) (Supplemental Table 4 ). In sex and age-stratified analyses, adjusted HRMI for women (n = 2,295 MI) varied between 1. Figure 3B and Supplemental Table 4 ). Models adding the PCE-derived variable as a covariate did not show significant modification in HRMI for both sexes (Supplemental Table 5 ). Overall, there was a significant sex interaction (p = 0.002). When stratifying by age, significant sex interactions were only observed in the first (p = 0.001) and second (p = 0.012) quartiles. There was an inverse correlation between PRSCAD and age at first incident MI, with a Pearson's For each category stratified by both age and sex, we also verified the impact of being in the highest percentiles of the PRSCAD distribution on HRMI. Overall, the risk of incident MI increased gradually across percentiles for all quartiles of age, although confidence intervals were wider for higher thresholds (Figure 4 ). The 90 th percentile threshold corresponded to a HRMI above 2 in both sexes while higher thresholds showed modest increases in risk (Figure 4 and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure 4 and Supplemental Table 6 ). Kaplan-Meier estimates of cumulative events for MI were consistent with Cox regression results. When divided in tertiles, PRSCAD was significantly associated with a higher incidence, in all individuals ( Figure 5A -Log-rank test, p <0.0001), but also in both women and men (respectively Figures 5B and 5C -Log-rank test, p <0.0001). Taken together, a wider separation was observed for cumulative events curves in men (Supplemental Figure 6) . (Table 3 and Supplemental Table 7 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Age-stratified analysis showed different results in women and men. First, NRI 0.02 was low in women when stratified by age, likely due to an overall smaller number of cases (Table 3, Supplemental Table 7 and Supplemental Figure 8 ). In men, NRI 0.02 was higher in the first quartile of age (0.199 -95% CI [0.157 to 0.248]), mainly driven by the reclassification of events in the high-risk category (Supplemental Figure 8B) , and decreased over the other quartiles (Table 3 and Supplemental Table 7 ). NRI >0 showed at least modest improvement in all groups, ranging from 0.271 to 0.602 (Table 3 and Supplemental Table 7 ). We have evaluated the impact of PRSCAD on all-cause mortality. 23 Table 8 ). A sex interaction within all participants was observed, with a stronger association observed in men (p = 1.65e-06, Figure 6 ). In women (n=9,604 deaths), HRMORTALITY per SD increase of PRSCAD was significant (1.04 -95% CI [1.02 to 1.06], p = 3.17e-04), but when stratified by age quartiles, only in the first and last were significant ( Figure 6A and Supplemental Table 8 ). In men (n = 14,378 deaths), HRMORTALITY per SD increase of PRSCAD were significant for all age groups; the strongest association was observed in the youngest group (aged between 40 and 51 years) with a corresponding HR of 1.15 (95% CI [1.08 to 1.22], p = 1.64e-05) ( Figure 6B and Supplemental Table 8 ). As observed for incident MI, being in the highest percentiles of PRSCAD was associated with a significantly higher risk of mortality (Supplemental Figure 9 and Supplemental Figure 9 and Supplemental Table 9 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Kaplan-Meier curves showed modest but significant separation of survival curves among tertiles of PRSCAD in women (Log-rank test, p = 0.02, Figure 7B) , and a significant separation in survival curves was observed in men (Log-rank test, p < 0.0001, Figure 7C ). After 10 years of follow-up, cumulative mortality estimates ranged between 3.61% (low PRS) and 3.78% (high PRS) in women, and between 5.92% (low PRS) and 7.11% (high PRS) in men. Individuals above the 90 th percentile threshold presented overall 10-year cumulative mortality of 4.11% and 7.41%, respectively for women and men (Supplemental Figure 10 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We derived a polygenic risk score for CAD using a recognized Bayesian approach and evaluated its predictive accuracy for incident myocardial infarction and all-cause mortality, in various age and sex groups using recent data from UK Biobank. Our study supports 4 major conclusions. First, the association between PRSCAD and incident MI varies according to age and sex. Younger men (aged between 40 and 51 years) showed significantly higher HRMI compared to the other groups tested. Recently, sex-stratified Cox regressions using different PRSCAD in UKB revealed higher HRs for incident CAD in men compared to women 25, 26 , although the analysis was not performed in all age groups. Another study in UKB with a mean follow-up period of 6.2 years showed that men with a high PRSCAD are at a significantly higher risk 17 . The better performance observed in men could be due to the overrepresentation of men as cases in CAD GWAS. The use of sex-specific association data could potentially improve the predictive accuracy of PRS, notably for women. Our results suggest a more important genetic component in early-onset events, as the prediction accuracy of MI incidence was the highest in the youngest quartiles of age in both women and men. This last observation is in line with a previous study showing that a genetic risk score of 182 variants was strongly associated with early-onset CAD (before 40 years old) 15 . A recent study in the FinnGen cohort reported that using the top decile of a PRSCAD including >6 million SNPs could identify 12.6% of coronary heart disease cases missed by clinical risk scores in individuals under 55 years old, compared to only 2.5% of cases in older individuals 22 . We also report a significant inverse correlation between PRSCAD and age at first incident MI in men, supporting the better performance to predict early-onset events. Second, PRSCAD was significantly associated with all-cause mortality in both sexes, with a stronger association in men. This is consistent with a recent study that showed an association between a PRSCAD (207 SNPs) and all-cause mortality in men only in UKB 23 . We also observed a small but significant difference in PRSCAD between age groups, with older individuals having on average a lower PRS. This finding could support a potential impact of PRSCAD on longevity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. showed no significant improvement in reclassification with models including both PCE and a PRSCAD of >6 million SNPs (versus PCE alone) in two cohorts (ARIC and MESA), even if the PRS was associated with the incidence of coronary heart disease. The discrepancy with our results could be in part due to the older population in these cohorts, which respectively included individuals with a mean age at baseline of 62.9 and 61.8 years (compared to 56.9 years in this study). The study by Elliott et al 19 in UKB, with a median follow-up of 8 years, showed a modest but significant categorized-NRI for incident CAD (risk threshold of 7.5%) when adding a PRSCAD of 1 million SNPs (derived using the lassosum method). Notably, the PRS had a higher predictive accuracy in participants <55 years, although reclassification analyses were not performed in specific age groups. In our study, discriminative capacity and NRI were significantly higher in the younger group of men, supporting a potential utility to predict earlyonset events. In fact, a PRS that can be measured from birth could improve the predictive performance of clinical scores which rely heavily on age and have lower predictive accuracy in young individuals. Fourth, we propose the use of a threshold to identify patients at high genetic risk of MI. We demonstrate that hazard ratios for MI for individuals in the top percentiles of the PRSCAD increase gradually. Women and men above the 90 th percentile of PRSCAD have a more than twofold increase in risk for incident MI and a 15 to 20% increase in risk of all-cause mortality. We therefore suggest the 90 th percentile of the distribution as a threshold to identify patients at high risk, in line with other studies 20, 22 . A similar threshold was previously used to identify patients with a high polygenic risk who benefit more from lipid-lowering treatments 12, 14, 20, 21 . Notably, a recent study showed that individuals with a PRSCAD including >6 millions of SNPs above the 90 th All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.25.21256083 doi: medRxiv preprint percentile had a higher benefit from alirocumab, a PCSK9 inhibitor, with significant reduction of absolute and relative risk. The data from the latter study was obtained from ODYSSEY OUTCOME, a clinical trial including patients with a previous diagnosis of CAD 20 . Similar results were observed in statin trials for primary prevention 12, 14 . All in all, the 90 th percentile of PRSCAD could be used as a threshold to identify high-risk individuals for selection in clinical trials and the use of more aggressive preventative measures. Our study has limitations. First, our analyses were restricted to events occurring after the age of 40, the minimum age at recruitment in UKB. In addition, individuals with a very high genetic risk could be underrepresented in the older groups since they are more likely to have early-onset events. Second, this study is limited to individuals of European ancestry. Results need to be validated in other ethnic groups. Third, the number of events was lower for women than men, which may have decreased the power to detect significant associations. Fourth, the PCE is validated for ASCVD and not specifically to predict MI. MI was selected as the main outcome for incident analyses because of its severity and more robust phenotype. In conclusion, we show that a polygenic risk score for CAD is independently associated with incident MI and all-cause mortality, and has a better predictive accuracy in men between 40 and 51 years old. The use of a PRS threshold to identify individuals at high risk of an early-onset MI should be considered. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.25.21256083 doi: medRxiv preprint Figure 6 : Association between PRSCAD and all-cause mortality. Cox regression results were obtained from models adjusted for age and the first ten genetic principal components in women (A) and in men (B), by quartiles of age (Q1 to Q4) and for the whole group (all ages). Data are presented as estimated hazard ratios (HR) for mortality per SD increase of PRSCAD, with their 95% confidence interval (95% CI). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. included All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study Genetic risk, adherence to a healthy lifestyle, and coronary disease Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease Guideline on the Assessment of Cardiovascular Risk Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report from the American Heart Association and American College of Cardiology A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting Polygenic Contribution in Individuals With Early-Onset Coronary Artery Disease Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the ODYSSEY OUTCOMES Trial Predicting Benefit from Evolocumab Therapy in Patients with Atherosclerotic Disease Using a Genetic Risk Score Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease Sexual Differences in Genetic Predisposition of Coronary Artery Disease An Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction. Circulation: Genomic and Precision Medicine 2021 We would like to thank all study participants and scientists involved in the UK Biobank study. BJA and ST hold junior scholar awards from the FRQS. YB holds a Canada Research Chair in All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.25.21256083 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 27, 2021. BJA is a consultant for Novartis and Silence Therapeutics and has received research funding from Pfizer and Ionis Pharmaceuticals. PM is a consultant for Casebia Therapeutics.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 27, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 27, 2021.